Close
Newsletter
Subscribe to our newsletter
Picture of The Ethical Challenges of the Stem Cell Revolution

The Ethical Challenges of the Stem Cell Revolution

Author(s): Audrey R. Chapman
Contributors: Audrey Chapman;

Book Description

Stem cells, particularly pluripotent stem cells, hold significant promise for developing therapies for diseases and disorders for which there are no current treatments and for regenerating human cells, tissues, and possibly even organs. However, to be able to translate stem cell research into therapies, researchers must first address many scientific, ethical, and regulatory hurdles. The need for researchers and sponsors to demonstrate progress and the hopes of patient groups for new therapies have pressured researchers to move quickly into clinical trials and encouraged the opening of clinics offering unproven and unapproved stem cell treatments. This book tells the story of the development of the field, and identifies the ethical issues and challenges stem cell translation raises. It will be of interest to ethicists, scientists, and regulators working in the stem cell field, as well as the general reader following scientific developments.

Hardback

ISBN-13: 978-1-5275-5587-7
ISBN-10: 1-5275-5587-9
Date of Publication: 01/10/2020
Pages / Size: 199 / A5
Price: £58.99
:

Biography

Audrey R. Chapman, PhD, holds the Healey Memorial Chair in Medical Ethics at the University of Connecticut School of Medicine and is a Professor of Community Medicine and Healthcare. She is the author, co-author, and editor of 16 books and more than 100 peer-reviewed articles, reports, and book chapters on ethical and human rights issues related to human embryonic stem cell research, genetics, germline modification, health care access, and clinical trials. Her most recent books are Global Health, Human Rights and the Challenges of Neoliberal Policies (2016) and Genetic Research on Addiction: Ethics, the Law, and Public Health (2012). She has served as Chair of the University of Connecticut Stem Cell Research Oversight Committee for some 10 years, and is a member of the Expert Genomics Panel for the Connecticut Department of Public Health and the Maryland State Stem Cell Review Committee.